Biophytis shares are trading higher after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.
Portfolio Pulse from Benzinga Newsdesk
Biophytis and Skyepharma have signed a partnership agreement for the production of regulatory batches of Sarconeos (BIO101), a treatment for severe forms of Covid-19. This has led to an increase in Biophytis' share price.
September 25, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biophytis' shares are trading higher following the announcement of a partnership with Skyepharma for the production of Sarconeos.
The partnership with Skyepharma for the production of Sarconeos, a treatment for severe forms of Covid-19, is a positive development for Biophytis. This could potentially increase the company's revenues and profitability, leading to a rise in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100